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Abstract
Background: Previous studies indicated that recombinant gas vesicles (r-GV) from a mutant strain
of Halobacterium sp. NRC-1 could express a cassette containing test sequences of SIVmac gag
derived DNA, and function as an antigen display/delivery system. Tests using mice indicated that
the humoral immune response to the gag encoded sequences evoked immunologic memory in the
absence of an exogenous adjuvant.
Results: The goal of this research was to extend this demonstration to diverse gene sequences by
testing recombinant gas vesicles displaying peptides encoded by different SIV genes (SIVtat, rev or nef).
Verification that different peptides can be successfully incorporated into the GvpC surface protein
of gas vesicle would support a more general biotechnology application of this potential display/
delivery system. Selected SIVsm-GvpC fusion peptides were generated by creating and expressing
fusion genes, then assessing the resulting recombinant gas vesicles for SIV peptide specific antigenic
and immunogenic capabilities. Results from these analyses support three conclusions: (i) Different
recombinant gvpC-SIV genes will support the biosynthesis of chimeric, GvpC fusion proteins which
are incorporated into the gas vesicles and generate functional organelles. (ii) Monkey antibody
elicited by in vivo infection with SHIV recognizes these expressed SIV sequences in the fusion
proteins encoded by the gvpC-SIV fusion genes as SIV peptides. (iii) Test of antiserum elicited by
immunizing mice with recombinant gas vesicles demonstrated notable and long term antibody
titers. The observed level of humoral responses, and the maintenance of elevated responses to,
Tat, Rev and Nef1 encoded peptides carried by the respective r-GV, are consistent with the
suggestion that in vivo there may be a natural and slow release of epitope over time.
Conclusion: The findings therefore suggest that in addition to providing information about these
specific inserts, r-GV displaying peptide inserts from other relevant pathogens could have significant
biotechnological potential for display and delivery, or serve as a cost effective initial screen of
pathogen derived peptides naturally expressed during infections in vivo.
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Background
The goal of this research was to generate and test an inno-
vative, cost effective antigen display and delivery system
that uses micro particulate gas vesicles (GV). Although it
has been long known that portions (epitopes) of mole-
cules can be recognized by the immune system and the
antibodies stimulated against the correct epitope(s) can
elicit protective immunity, recently there has been signifi-
cantly increased interest in the exploration of novel
approaches to vaccine development and immunogen
delivery. Thus growth of biotechnology and development
of new tools now support the important expansion to
include a diversity of new aspects that support moving
beyond conventional immunization approaches and
obtaining new information defining vaccine components
[1-3].
Halobacterium sp. NRC-1 is a remarkable organism that
exhibits a number of characteristics that are significant to
its biotechnology utility. Culturing is simple, DNA medi-
ated transformation may be accomplished at high effi-
ciency and proteins and organelles can be released from
the halobacteria by simple lysis in hypotonic medium.
The  Halobacterium sp. NRC-1 genome is completely
sequenced [4] and the genomic data supports a wide
range of studies that enhance its potential for commercial
uses, as well as basic biochemical analyses of adaptation
to extreme conditions. In addition, both an halobacte-
rium transformation system [5,6] and E. coli/Halobacte-
rium sp. shuttle plasmids, developed for basic genetic
studies, are directly applicable to biotechnological appli-
cations. The cell envelope of Halobacterium salinarum con-
sists of a single lipid bilayer membrane surrounded by an
S-layer assembled from the cell-surface glycoprotein. This
fact is important in terms of simple release of gas vesicles,
or cytosolic proteins, from the organism. The gas vesicles
themselves are unique organelles naturally produced by
halophilic archaea and their biogenesis is inherently qual-
ity controlled by the organism. Fourteen gvp genes have
been identified as encoding components involved in the
genesis of organelles, and the regulation of gvp  gene
expression has been shown to occur at the transcriptional
and translational levels [7-10].
Gas vesicle organelles are cylindrical-shaped particles with
conical ends about 200 nm long, and composed of an
inflexible, thin (20Å) proteinaceous (lipid free) mem-
brane [11-13] that encloses a gas-filled space. The lipid
free membranes form a barrier to liquids but are permea-
ble to many dissolved gases such as nitrogen, oxygen, car-
bon dioxide and methane. The membrane has an
extremely stable, two-dimensional crystalline lattice com-
posed of two major proteins, GvpA and GvpC. The GvpA
protein is highly conserved and forms a linear crystalline
array of ribs that form the cylindrical shell and conical
ends of the gas vesicle. GvpC is located on the vesicle
outer surfaces and adds strength, stability and shape. Pre-
vious findings suggested that GvpC is present on the exter-
nal surface of the vesicle and functions as a "molecular
glue" to enhance the membrane stability [14]. With regard
to peptide display, these characteristics are desirable in
terms of antigen presentation and are potentially impor-
tant for applications involving epitope display, a key for
vaccine development. In this context, previous findings
indicate there is no evidence of harmful effects from con-
suming native halobacteria [15,16] so that recombinant
gas vesicles should be suitable for use in oral as well as
parenteral delivery.
Electron microscopy has demonstrated that the surface of
the GV itself is highly organized suggesting it would sup-
port organized presentation of encoded antigen, and it is
known that these stable protein structures themselves can
provide an intrinsic adjuvant activity. Preliminary evi-
dence demonstrated that gas vesicles can be genetically
manipulated to display peptides coded by an insert of
irrelevant DNA that specified a sequence of six amino
acids, and peptide immunogenecity and antigenicity were
verified both in vitro and in vivo [17,18]. Initial studies
with the gag gene from SIVmac have raised the possible
utility as a display/delivery system using gas vesicles to
present pathogen peptide sequences up to 235 amino
acids; these results also suggested the recombinant
organelles were intrinsically self-adjuvanting [18,19].
Thus the preceding studies indicated the GvpC protein is
sufficiently flexible to tolerate exogenous sequence inserts
and thus support the principle of gas vesicles as a recom-
binant component for pathogen display/delivery. The
studies presented below tested the generalized applicabil-
ity of this technology using selected DNA segments
encoding pathogen peptide sequences of diverse size and
native gene function. These were assessed for plasmid
retention of the exogenous DNA sequences, gas vesicle
retention of the recombinant protein and the long term
maintenance of elicited humoral responses to the exoge-
nous peptide sequences displayed by the r-GvpC protein
that had been incorporated into the organelle.
Results
Our earlier studies to generate recombinant gas vesicles
provided evidence that when inserted into an appropriate
site in the gvpC gene, this halobacterial gene would accept
SIV gag gene DNA segments of different lengths and the
resultant sub microscopic organelles would express this
recombinant protein at the gas vesicle surface [19]. To
demonstrate the potential flexibility and gene independ-
ent nature of surface expression using this cassette based
system, we applied the methods outlined below and pre-
pared a series of 21 different plasmids that encompassed
the entire SIV genome. The three gene segments selectedBMC Biotechnology 2008, 8:9 http://www.biomedcentral.com/1472-6750/8/9
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for detailed study were used to transform the Vac- mutant
Halobacterium sp. NRC-1, strain SD109 to obtain recom-
binant gas vesicles. After expanding the different initial
transformant populations, the functional expression of
the three fragments, each representing a different insert
length and a different gene, was then tested through
assessments of the gas vesicles produced. Functional
(floating) recombinant gas vesicles were readily isolated
from each of the transformants and then tested to detect
recombinant GvpC expressing the SIVTat, Rev or Nef1 encoded
peptide and assessed for recognition as SIV genome
derived using sera from an SHIV infected monkey. They
then were used to immunize mice in order to test for their
capacity to stimulate peptide specific humoral response in
the absence of exogenous adjuvant and for the retention
of titers for an extended time period.
Generation of DNA components
The 21 segments constituting the SIV genome were suc-
cessfully amplified previously and for larger genes, e.g.
Nef, the multiple fragments of the same gene were num-
bered numerically starting at the amino terminal end.
Table 1 shows the PCR primers used to amplify the spe-
cific gene segments studied in detail here as well as the
primers for the 350 bp internal segment amplified from
the gvpC  gene. The individual SIV gene segments were
then expanded, using pUC19 and transformation of E. coli
DH5α, followed by cloning into a second vector
pFM101d shown in Figure 1. Following the steps outlined
in the Methods section, the selected blunt end SIV frag-
ments were then ligated into an Eco47 III site in the gvpC
gene at the position designated as "d" in the rightward
operon in the plasmid pFM101d and used for the trans-
formation of E. coli. After expanding E. coli transformants,
rightward operons with their SIV derived DNA insert were
harvested from the plasmids using the Spe I and AsiS I.
Each recombinant operon was then ligated into plasmid
pMS104d using the methods described previously for
pFM104d [19].
In order to confirm that these plasmids retained the
inserted SIV DNA sequences, the DNA was isolated from
each different transformant population, and from the
wild type, Halobacterium sp. NRC-1. Using the appropriate
forward and reverse primer specific for the gvpC gene of
each of the incorporated SIV derived DNA segments and
shown in Table 1, the DNA was PCR amplified. As shown
by the agarose gel in Figure 2, these amplification prod-
ucts indeed demonstrated the expected size relative to the
1 kb standard and to the Control (C), the internal 350 bp
fragment from the native gvpC gene of Halobacterium sp.
NRC-1. The electrophoretic mobility of amplification
products demonstrates successive increases in base pair
(bp) sizes, fully consistent with the selected SIV genomic
DNA inserts. As the amplicons of the DNA inserts demon-
strate, each of the three different exogenous DNA
sequences had been stably retained in the recombinant
gvpC gene contained in the rightward gas vesicle operon.
Transformation of Vac- Halobacterium strain SD109
The Vac- (minus) mutant, Halobacterium  strain SD109
lacks the entire gas vesicle gene cluster and was used for
Strategy for incorporating SIV DNA sequences into the gvpC  gene carried in plasmid pFM101d Figure 1
Strategy for incorporating SIV DNA sequences into 
the gvpC gene carried in plasmid pFM101d. Plasmid 
pFM101d contains the rightward gas vesicles operon with the 
gvp genes (A, C and N). A unique Eco47 III site at location 
"d", within the gvpC gene, allowed insertion of the exogenous 
DNA fragments. The unique restriction enzyme sites Spe I, 
AsiS I and Afl II allowed manipulation/isolation of this cluster 
of gas vesicle genes by appropriate restriction digests. The 
antibiotic resistance genes are indicated with the boxes and 
allow selection of transformed E. coli or SD109 using Ampici-
lin (Amp) and Mevinolin (mev), respectively.
A 
C 
N 
Spe I 
AsiS I Eco47 III 
SIV 
pFM101d 
   7.4 Kb 
Amp
r 
    ori 
(ColE1) 
mev 
Afl II 
Table 1: Primers sequences for PCR amplification of DNA 
encoding the proteins examined here.
Fragments Primers Sequence (5' to 3') Size (bp)
Tat Tat F ggg atg gag aca ccc ttg aag 150
Tat R ggg atg ata gca aca cct ctt
Rev Rev F ggg tca gca gat ccc tat cca 243
Rev R ggg cgg act ctt tgc aac gtc
Nef1 Nef1 F ggg atg ggt ggc gct att tcc 642
Nef1 R ggg ctt cca tgc cag tac ctc
gvpC gvpC F ctc ctg ctg tga ttc tgc ga 1,070
gvpC R cat cct cac cgt act cgt cg
gvpC – Kpn I cta tgg cca cga gat cac g 350
DNA sequences required to generate recombinant GvpC and 
demonstrate the successful insertion and retention of test SIV DNA 
sequences utilized PCR amplification and the forward (F) and 
reverse(R) primers listed above.BMC Biotechnology 2008, 8:9 http://www.biomedcentral.com/1472-6750/8/9
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transformation following the protocols described in the
Methods. Spheroplasts were prepared from the Vac-
SD109 strain and can be readily distinguished from the
normal rod shape of these halobacteria by microscopic
examination (Figure 3A and 3B). This fact supports simple
and straightforward verification that the spheroplast form
required for transformation of the Vac- mutant has been
achieved. The spheroplasts were then transformed using
pMS104D::tat, ::rev  or ::nef1  and methods described
below. The putative SD109 transformants were cultured
under mevinolin selection and could be readily assessed
for gas vesicle production. As seen in the comparison of
liquid cultures shown in Figure 4, Vac- and Vac+ cultures
are readily distinguishable. Figure 4A shows the slightly
cloudy appearance of a Vac- SD109 culture which appears
brownish orange in color. In contrast, Figure 4B–C show
the typical milky white culture appearance of the gas ves-
icle containing wild type Halobacterium sp. NRC-1 or suc-
cessfully transformed SD109 strain. Similarly, visual
inspections of transformants grown on plate media,
shown in Figure 4D, also supports visual tracking for suc-
cessful transformation to produce Vac+  (plus) recom-
binants. Figure 4E shows examples of isolated r-GV and
these clearly display the characteristic pink-tinged white
band of gas vesicles at the interface of the 5% NaCl solu-
tion with the overlaying air; GV flotation at this interface
verified that the recombinant GV are functional.
Thus the initial findings have been verified and extended
to transformations using inserts of diverse DNA sizes and
encoded gene function. This is a key step in r-GV produc-
tion and the generation of functional product that can be
readily harvested. The actual biosynthesis of the gas vesi-
cle product and the retention of gas vesicle function, i.e.
floatation of the isolated product, can be readily assessed
visually. In combination, these findings demonstrate that
the transformations with each of the selected recom-
binant plasmids (pMS104D::tat, ::rev and ::nef1) were suc-
cessful and had conferred a functional, Vac+ status to the
recipient SD109 Vac- mutants, irrespective of the insert
selected for these studies, or its native function.
Identification of the recombinant GV proteins by Western 
blot
In our earlier studies the GvpC protein was clearly evident
when anti-GvpC antiserum was used. Recombinant
Spheroplast formation by the gas vesicle deficient strain  SD109 results in a distinctive, spherical morphology Figure 3
Spheroplast formation by the gas vesicle deficient 
strain SD109 results in a distinctive, spherical mor-
phology. With the addition of spheroplasting solution and 
0.5 M EDTA, the rod shape halobacteria cells (Panel A) rap-
idly changes into the transformable spheroplast form (Panel 
B) exhibiting a characteristic change in morphology detecti-
ble microscopically. Spheroplasts can then be transformed 
with the recombinant plasmids pMS104D::tat,::rev or ::nef1 
carrying the native leftward operon of the gas vesicle gene 
cluster and the rightward operon carrying an inserted SIV 
fragment of interest. Original magnifications 1,000 ×.
A  B 
Verification of SIV DNA sequence retention in the gvpC gene  following plasmid amplification Figure 2
Verification of SIV DNA sequence retention in the 
gvpC gene following plasmid amplification. Following 
expansion of the pFM101D-SIV tat, rev and nef1 plasmid pop-
ulations, DNA was tested for retention of the SIV specific 
insert carried by the recombinant gvpC genes. The agarose 
gel shows the PCR amplicon sizes of the selected SIV gene 
fragments and are indicated along the horizontal axis: tat:150, 
rev:243 and nef1:642 bp. Their presence inherently verifies 
SIV DNA retention by each r-gvpC genes. The Control (C) is 
an internal fragment from the gvpC gene and serves as a 
marker for the migration of this 350 bp fragment. The rele-
vant primers are shown in Table 1.
  bp             Tat   Rev   C   Nef1 
1000 -
  750 -
  500 -
  250 - 
  150 243  350  642 bpBMC Biotechnology 2008, 8:9 http://www.biomedcentral.com/1472-6750/8/9
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SIVsm-GvpC protein expressing sequences of the gag gene
was identifiable using antiserum from SIVsm challenged
monkeys and standard ELISA titration of gas vesicles con-
taining chimeric SIVsm-GvpCGag  protein demonstrated
the presence of recognizable SIV gag gene insert expressed
by r-GvpCGag [19]. To demonstrate that the expression of
recombinant peptide originally examined using a gag
sequence was not insert specific or unique, this study
examined recombinant SD109 transformants expression
of the three different SIV encoded peptides within the
framework of recombinant GvpC protein. Gas vesicles
were isolated from independent, replicate cultures of each
of the different recombinant populations. These were ana-
lyzed by Western blot for the presence of recombinant
GvpC protein exhibiting the anticipated increase in
molecular weight and recognition by the specific anti-
GvpC antibody. Although halobacterial proteins behave
anomalously in analyses using the standard analytical
technique of SDS-PAGE [20], nevertheless the approxi-
mate molecular weight (MW) can be assessed by adding
the molecular weight of the SIV insert to apparent molec-
ular weight previously demonstrated in this system. The
results are shown in Table 2 and indicate that the SDS-
PAGE technique should readily detect altered electro-
phoretic mobility reflecting insert associated size differ-
ences. Gas vesicles putatively expressing recombinant
GvpC containing Tat, Rev or Nef1 peptides were isolated
from the appropriately transformed SD109 cultures. Gas
vesicles similarly isolated from wild type organisms, Halo-
bacterium sp. NRC-1, provided the molecular weight
marker for the wild type GvpC protein used in the
immuno-identifications. Using standard protocols for
SDS-PAGE and then Western blots, all samples were trans-
ferred to Immobilon membranes and probed with appro-
priate antibodies to detect the proteins of interest.
GvpC protein was identified by Western blot membrane
incubation with anti-GvpC rabbit serum generated by
immunizations using a lacZ-GvpC fusion protein and
noted previously [14,19]. Gas vesicle preparations were
isolated from populations transformed to incorporate Tat
or Rev amino acid sequences. As Figure 5 demonstrates,
the anti-GvpC antibody recognized GvpC contained in
the putative fusion proteins. As this Western blot also
indicates, characteristic differences in apparent molecular
Table 2: Molecular Weight and pI for the proteins examined 
here.
Characteristics GvpC Tat Rev Nef1
pI 3.73 4.92 8.17 5.31
pI (Fusion proteins) 3.83 3.88 4.07
MW (Da) 42,392 5,743 9,313 24,733
Expected MW† 48,117 51,687 67,106
Predicted MW‡ 60,000 65,743 69,313 84,733
† Expected MW is calculated as GvpC + SIV insert; Tat, Rev and Nef1 
respectively.
‡ Predicted MW is based on results for GvpC from wild type GV 
(NRC-1) where the protein band was indicated at ~ 60 kDa [18]. 
Accordingly, the MW for the recombinant proteins was calculated as 
a sum of the specific insert and the MW for the GvpC. Isoelectric 
points were calculated using the Web page for pI/MW calculation 
[42].
Growth by SD109 transformants producing gas vesicles is visually distinguishable from the Vac-SD109 mutant Figure 4
Growth by SD109 transformants producing gas vesicles is visually distinguishable from the Vac-SD109 mutant. 
Panels A-E show typical cultures of wild type or transformed halobacteria. Panel A: the gas vesicle deficient (GV-) strain 
SD109 which in natural color exhibits a characteristic rust brown appearance; Panel B: a culture of the wild type gas vesicles 
(GV+) from Halobacterium sp. NRC-1, exhibits the characteristic milky appearance of GV+ cultures. Panel C: a culture of trans-
formed halobacteria strain SD109 expressing the nef1 encoded peptide exhibits the characteristic rounded morphology of GV+ 
cultures when plated on agar media with the slightly pink tinged white coloration. Panels D and E: Isolated recombinant gas 
vesicles, like the native ones are evident as a white ring at the interface of the air/5% NaCl solution. Flotation of the r-GV to 
this interface verifies the chimeric GV isolated from SD109 transformed with pMS104D::tat or ::nef1 are functional.
A B C D EBMC Biotechnology 2008, 8:9 http://www.biomedcentral.com/1472-6750/8/9
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weight are evident for the recombinant bands recognized
by the anti-GvpC antibody. These differences allow dis-
crimination from the wild type GvpC protein (see in Fig-
ure 6, Panel A), and are consistent with an expected
differentially increased molecular weight of the recom-
binant GvpC proteins produced by the transformants. The
differences also are consistent with the anomalous behav-
iour of halobacterial gas vesicle proteins when analyzed
by SDS-PAGE gels.
A comparison with the migration of native GvpC released
from wild type gas vesicles in the lane labeled wt (NRC-1),
a control included in Figure 6, shows the normal mobility
of this wild type protein (Panel A). At the left side of Fig-
ure 6, Panel A shows the anti-GvpC antisera recognizes
GvpC of wild type NRC-1 gas vesicles, while Panel B dem-
onstrates that the anti-SHIV monkey sera does not recog-
nize wild type GvpC. Panel C provides evidence that this
same anti-SHIV monkey serum does recognize SIV
encoded peptides within the recombinant GvpC protein
(r-GvpCTat, and r-GvpCRev). Thus, as expected based on
Table 2, the Western blots have demonstrated the
expected increased apparent molecular weight of the r-
GvpC proteins. More importantly, the fact that anti-SHIV
monkey serum fails to recognize wild type GvpC validates
this plasma for specific detection of SIV peptide inserts.
Recognition of the Nef1 peptide contained within the chi-
meric GvpC protein was similarly demonstrated. Panel A
of Figure 7 shows a Coomassie blue stained SDS PAGE gel
analysis for r-GvpCNef1 presence in isolated recombinant
gas vesicles or lysate of SD109 cells transformed with the
pMS104D::nef1. Panel B of Figure 7 is a Western blot of
these same samples and demonstrates that antisera from
Immunoblots verify nef1 DNA also is expressed by r- GvpCNef1 and carried by recombinant gas vesicles Figure 7
Immunoblots verify nef1 DNA also is expressed by r-
GvpCNef1 and carried by recombinant gas vesicles. 
SDS-PAGE and Western blots demonstrate that Nef1 also is 
successfully expressed and can be detected in lysates and r-
GV of SD109 transformed with pMS104D::nef1. The 
Coomassie Blue stained 12% SDS-PAGE gels shows resolu-
tion of proteins in gas vesicles or lysates from these trans-
formed SD109 cultures (Panel A). Duplicates of these 
resolved proteins were electroblotted (Panel B) and the 
presence of the Nef1 peptide in chimeric r-GvpC, identified 
by both absorbed anti-Nef1 sera from mice immunized with 
r-GVNef1 and the monkey anti-SHIV antibody (plasma number 
R94085). Antibody binding shows recognition of Nef1 pep-
tide within the recombinant GvpC protein. The mouse anti-
Nef1 serum was used at a 1:250 dilution; the monkey anti-
SHIV antibody was used at a 1:200 dilution. The standards 
(kDa) are shown on the left and the immuno detected band 
for recombinant Nef1 containing r-GvpC protein is identified 
on the right.
  - Nef1 
 
                                                           Mouse          Monkey
                                               Cell        anti-                anti-         Cell 
 kDa     GV     MW     GV       lysate     Nef1    MW     SHIV       lysate 
A B 
98 -  
 
64 - 
 
50 - 
Verification of recombinant GvpC protein formation and  incorporation into functional gas vesicles Figure 5
Verification of recombinant GvpC protein formation 
and incorporation into functional gas vesicles. West-
ern blots were used to assess putative recombinant gas vesi-
cles (Panel A) and cell lysates (Panel B) for the presence of 
r-GvpC protein. Here samples are resolved in 8–16% SDS-
PAGE gels, immunoblotted and probed with rabbit anti-
GvpC antibody. The size range of the protein standards 
(kDa) is indicated at the left and the recombinant GvpC pro-
tein bands are identified at the right.
  -T a t
  - Rev
  kDa Gas vesicles MW  Cell lysates 
A B 
98 -  
 
64 - 
 
50 - 
Verification that recombinant gas vesicles have GvpC pro- teins containing both halobacterial and SIV encoded peptides Figure 6
Verification that recombinant gas vesicles have GvpC 
proteins containing both halobacterial and SIV 
encoded peptides. Western blots of putative recombinant 
gas vesicle samples from cultures of SD109 transformed with 
pMS104D::tat or ::rev demonstrate the presence of chimeric 
GvpC proteins. Electroblotted wild type gas vesicles samples 
(wt-GV) prepared from the NRC-1 were incubated with 
purified rabbit anti-GvpC antibody or with monkey anti-SHIV 
antibody. As shown, the GvpC protein is clearly detected by 
anti-GvpC antibody (Panel A), but this protein is not 
detected by anti-SHIV antibody (Panel B). In cell lysates, Tat 
and Rev sequences contained in the putative recombinant 
GvpC protein are each detected using anti-SHIV antibody 
(plasma number R94085) from a monkey infected in vivo with 
SHIV virus (Panel C). The recombinant chimeric protein 
bands identified here correspond in size to bands identified 
with anti-GvpC antibody (see Figure 5 Panel B).
  - Tat 
- Rev 
  kDa       wt GV       MW  Cell lysates 
98 -  
 
64 - 
 
50 -  A B  C BMC Biotechnology 2008, 8:9 http://www.biomedcentral.com/1472-6750/8/9
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mice immunized with r-GVNef1 and also monkey anti-
SHIV sera each recognize the chimeric r-GvpCNef1 protein.
Thus the results demonstrate the Nef1 peptide sequence is
expressed and retained by the recombinant gas vesicles
used in murine immunizations. Equally important, recog-
nition by the anti-SHIV monkey serum demonstrates that
like chimeric Tat and Rev peptide containing GvpC pro-
teins, the Nef1 chimeric protein is also perceived as con-
taining the SIV derived peptide.
ELISA Assessments
To verify the immunogenecity of these recombinant gas
vesicles and test the critical parameter, presence of the
humoral immune response, mice were immunized with
recombinant gas vesicles and their antibody responses to
the SIV derived inserts assessed. Immunizations followed
the methods and injection schedule outlined in the Meth-
ods and used isolated r-GVTat, Rev or Nef1, gas vesicles pro-
duced by mutant halobacteria SD109 transformed with
the plasmids pMS104D-SIV::tat, ::rev, or ::nef1. The serum
samples drawn at various post-immunization time points
were assayed by ELISA. Sera samples, fully pre-adsorbed
with wt-GV as described in the Methods, were assayed to
detect SIV insert specific antibody recognition by using r-
GV produced by the homologous transformants and the
average absorbances at 405 nm were graphed. Figure 8
presents these results in the separate three dimensional
data displays and these show the sera titers at the different
times during the course of immunizations. Inherently
these humoral responses demonstrate the immunogenec-
ity of each of the incorporated SIV peptides displayed by
these three different r-GV. Each r-GV elicits a solid peptide
specific antibody response to the initial low dose, demon-
strates a secondary response to the booster and a natural
waning of antibody titer over time, as shown by assay of
the 12 week post booster sera. In addition, the develop-
ment of an immune response inherently demonstrates
both the presence of the displayed r-GvpC protein and,
because the sera were fully pre-adsorbed, the immune sys-
tem "visibility" of the specific SIV inserts. The titration
data also hint that differences in the responses to the dif-
ferent inserts might not be closely linked to the actual size
of SIV encoded peptide; the responses to the Tat insert (50
amino acids) was clearly more robust than the response to
the Rev insert (81 amino acids). This might provide a sim-
ple and useful method to screen peptide segments that
could provide an index of inherent capacity to elicit
humoral responses, although additional studies would be
required to demonstrate and verify ELISA based detection
of inherent immunogenicity.
Features critical to immunization based protection also
include the continued presence of elevated antigen spe-
cific antibody and the occurrence of such responses, inde-
pendent of the specific peptide tested. Figure 9 presents
ELISA titration data showing the antibody levels remain-
ing 43 weeks after a re-immunizing booster with the
homologous r-Gv. For the group immunized with r-GVRev
only one animal remained at this very late time point; its
serum titered at ~1:160. For the animals in the groups
immunized with r-GVTat  or r-GVNef1, very substantial
insert specific antibody titers (~1:1280 and 1:640)
remained at the 43 week time point. This finding supports
the conclusion that the humoral response to diverse pep-
tides expressed using the r-GV display/delivery system can
remain notably elevated. Potentially this would result
from a slow release of proteins from the gas vesicle as it is
degraded intracellularly and in vitro studies indicate this is
the case (manuscript in preparation). The system there-
fore exhibits a characteristic desirable in an immunizing
agent. In addition, the absence of exogenous adjuvant in
this system provides additional evidence of the self adju-
vanting characteristic of the recombinant gas vesicle deliv-
ery vehicle.
Discussion
In a previous study we demonstrated immunologic mem-
ory for the peptide expressed by r-GV was elicited, how-
ever the assessments of r-GV in that study involved only
the expression of peptide sequences from a single SIV gag
gene [19]. The ELISA data presented here tested quite dif-
ferent peptide sequences incorporated into the r-GvpC
protein and the results indicate that in this context, these
too are stimulatory and immune visible. The results pre-
sented above extend and strengthen the initial hypothesis
that r-GV can serve as a flexible cassette based epitope dis-
play/delivery system that supports expression of genes or
gene segments encoding peptides from proteins repre-
senting diverse functions in their native context. Here we
tested peptides encoded by three different SIVsm genes.
The Tat protein can function indirectly to promote virus
replication via receptor mediated signal transduction,
while intracellularly Tat normally is transported into the
host cell nucleus. The protein is essential for viral replica-
tion and is currently a candidate vaccine component. Rev
functions as a nucleocytoplasmic shuttling protein nor-
mally found primarily in host cell nuclei/nucleoli. One of
its functions is to "escort" unspliced viral mRNA out of the
nucleus. In contrast, Nef is a peripheral membrane pro-
tein, and appears to have a linker function, among others.
Thus Nef mediates a variety of protein-protein interac-
tions via its SH3 binding surface and down regulates MHC
class I, and CD4 expression, perhaps through its capacity
as a linker. Nef therefore can exert significant effects on
the host cell functions [21-27]. From the data presented
here, clearly the DNA segments tested, representing
sequences from proteins with significant inherent func-
tional differences, were stably incorporated into the gvpC
gene. The data also shows the insert peptide is retained in
the recombinant GvpC protein, and the chimeric proteinsBMC Biotechnology 2008, 8:9 http://www.biomedcentral.com/1472-6750/8/9
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produced are effectively incorporated to produce recom-
binant gas vesicles. For all three test peptide sequences the
functionality of the r-GvpC was shown by the generation
of gas vesicles that float, and r-GvpC release from isolated
gas vesicles during sample preparation for SDS-PAGE, ver-
ifies r-GvpC were incorporation as part of the organelles
themselves. Likewise, immunogenicity was demonstrated
through the anti-peptide responses elicited. These demon-
strated r-GV effectiveness as a delivery vehicle and support
the conclusion that irrespective of the gene source, the dis-
played peptides are immune system visible and immuno-
stimulatory. The known structure of GV microparticles
and their resistance to degradation, support the sugges-
tion that these functional characteristics of this unusual
display system are keys to their effectiveness as an adju-
vant.
The basis of this self adjuvanting effect remains to be clar-
ified but characteristics of certain halobacterial proteins
may be relevant. Molecular chaperones are essential com-
ponents of organisms that function as part of the normal
physiology, and in response to stress, and pathology. A
molecular chaperone system also is present in Halobacte-
rium sp. NRC-1 and represented by the proteins DnaK,
DnaJ, GrpE, and Hsps1–4 (small heat shock proteins).
The peptide-binding function of Hsp's (heat shock pro-
teins) allows chaperon proteins such as Hsp70 (heat-
shock protein 70) to acquire antigenic proteins within
cells, even when administered outside the cell and thereby
induce priming of CD8+T lymphocytes in vivo. In addition
to peptide binding and delivery, Hsp70 also can assist as
a carrier of peptides or proteins that are effective immuno-
gens for B cells, CD4+, and CD8+T cells, in the absence of
Immunogen specific ELISA titrations of antibody elicited by rGVTat, Rev or Nef1 encoded sequences Figure 8
Immunogen specific ELISA titrations of antibody elicited by rGVTat, Rev or Nef1 encoded sequences. Mice were ini-
tially immunized using isolated r-GV and subsequently boosted as specified in the Methods. The three dimensional graphs dis-
play the temporal profiles of antigen specific antibody responses to the SIV peptide expressed within the GvpC protein. For 
Tat, all post-4 week samples exhibit a titer of ≥ 1:1,280 while for Rev, the maximal titer, 1:320 occurs in the week 2 post sec-
ond booster sera. For Nef1, the highest titer, 1:320, is evident in sera from week 8 post second booster and by the 12 week 
time point, only sera from the animals immunized with r-GV expressing Rev retained a peptide specific titer.
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an adjuvant. Thus it has been shown that the C-terminal
portion of Hsp70 (amino acids 359–610) induces human
monocytes to produce CC chemokines (chemotactic
cytokines), IL-12 (interleukin-12), TNF a (tumour necro-
sis factor alpha), as well as stimulating the maturation of
dendritic cells [28]. Additionally there is evidence that for
microbial Hsp, this C-terminal portion of Hsp70 is
involved as an adjuvant in the induction of the innate and
adaptive elements of the immune response [29].
The slow degradation of wt- and r-GV could readily initi-
ate Hsps up-regulation in the host cell. Therefore, the self-
adjuvanting characteristics of gas vesicles could be analo-
gous to the chaperon activities of Hsp 70, produced by the
host cells in response to perturbation by the gas vesicle
presence, and in fact there is a notable similarity between
the GvpC protein and the DnaK and DnaJ proteins. In
addition, or alternatively, the geometric display on gas
vesicle surfaces may be analogous to the display achieved
when bacterial S-layers are used. Such displays are known
to enhance immune responses [30].
Inherent features of Halobacterium sp. NRC-1 and their
biosynthesis of gas vesicles are highly relevant to biotech-
nological utilities and these are evident here, in the steps
to generate and test the recombinant organelles. The plas-
mid pFM101d allows simple insertion of exogenous DNA
cassettes and subsequent transfer into the Halobacterium
strain SD109 transformation vector. A simple restriction
digest cleavage of the rightward operon is followed by
ligation into pMS104d, the large (18.9 kb) plasmid used
to transfer the 14 genes needed for gas vesicle biogenesis.
As application of simple agarose gel analysis showed, suc-
cessful SD109 transformation can be readily assessed via
EtBr (Ethidium Bromide) staining to verify amplification
products with the appropriate bp sizes. The actual trans-
formation of plasmid recipient is readily achieved by a
one step treatment of the Vac- SD109 strain with sphero-
plasting solution. A cell wall, such as is characteristic of
gram positive or gram negative bacteria is not present in
these archaeal organisms. This fact simplifies transforma-
tion as well as the subsequent gas vesicle isolation proc-
esses. Further, spheroplast formation itself can be verified
by simple microscopic examination of the treated halo-
bacterial samples. The SD109 cells undergo a shape
change and exhibit a spherical rather than the normal rod
morphology (Figure 3). Such spheroplasts were readily
transformed without additional treatments by simple
incubation with isolated pMS104D::tat  ::rev:: or :: nef1
DNA. Similarly, successful transformation and appropri-
ate function of the genes transferred by the transforming
plasmid is also easily determined. For liquid media, the
formation of "creamy-white" halobacterial cultures vs. the
rust brown of Vac- SD109 cultures is diagnostic for gas ves-
icle production and readily evident by simple visual
inspection as seen in Figure 4.
The specific verifications provided here are keys in the
context of validating this system and the peptides tested.
First, as clearly shown, recombinant GvpC expressed by
the vesicles demonstrate an expected decrease in electro-
phoretic mobility vis-à-vis GvpC from gas vesicles pro-
duced by wild type Halobacterium sp. NRC-1. Second, in
the present study, the gene segments inserted into the
gvpC encode peptides from proteins exemplifying a vari-
ety of functions, and as Figures 5, 6, 7 showed, when dis-
played by r-GvpC, each one was recognized not only by
anti-GvpC antibody (Figure 5), validating retention of the
r-GvpC protein, but also by antibody elicited in vivo dur-
ing infection of monkeys with SHIV virus (Figures 6, 7).
Since the anti-SHIV antibody did not recognize wild type
GV protein (Figure 6B), the incorporated SIV peptides
were being specifically identified when displayed as part
of the r-GvpC protein which is present at sites all over the
gas vesicle surface. Thus the insert into the GvpC protein
is both immune system visible and accessible. Equally
important, display of the SIV peptides in this manner did
not abrogate their recognition by appropriate antisera.
Finally, it is also highly relevant that as the titration of sera
collected 43 weeks post re-immunization shows, titers
remained for all three peptides although at 1:160, the
anti-Rev titer was the lowest of the three. However, the
titer for Rev likely reflects the fact that only one animal in
this group was extant. At this very late time point the titers
r-GV immunizations elicit long lived antibody responses to  the displayed SIV specific peptide inserts Figure 9
r-GV immunizations elicit long lived antibody 
responses to the displayed SIV specific peptide 
inserts. Seventeen weeks after the second booster, mice 
were boosted again with homologous r-GV and then 
retained for 43 weeks. ELISA assessments of sera taken at 
week 43 demonstrate that notable titers remain at this very 
late time point: 1:160 for Rev; and for Tat and Nef1, the tit-
ers are ≥ 1:1,280. Note: for this graph the absorbance scale 
is 0.0 – 5.0 and note also that (*) indicates only one animal 
remained in the Rev group at 43 weeks.
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of the animals immunized with Nef1 and Tat r-GV
(~1:640 and 1,280) were very notably higher.
From the perspective of general utility and ease of recom-
binant production, the characteristic inherent in the sys-
tem used here and the effective incorporation of
exogenous pathogen DNA sequences, both were demon-
strated in the course of generating the recombinant gas
vesicles. The features critical to their unusual utility
include characteristics inherent to the gas vesicle organelle
itself as well as the Halobacteria sp. in which they form.
They are relevant to r-GV use in biotechnology applica-
tions such as a pathogen peptide display and/or delivery
system. Thus, despite the unusual intracellular environ-
ment that halophiles maintain, and the unusual nature of
their native proteins [31,32], the pathogen gene
sequences were retained and also translated with fidelity
in the halobacteria SD109 expression system as demon-
strated by SHIV antibody recognition. The recombinant
GvpC proteins themselves are incorporated into the gas
vesicle structures as demonstrated by r-GvpC release from
isolated organelles and recognition by both anti-GvpC
and anti-SHIV antibody. Inherently, the GvpC protein, as
the "molecular glue" for the organelle, is present at the
surface of recombinant gas vesicles [12]. In addition, as
previously published electron micrograph show, this sur-
face intrinsically exhibits a highly organized, patterned
surface [7,18]. Finally, gas vesicle formation itself is qual-
ity controlled by the gvp gene cluster carried by the trans-
formed SD109 strain and release of the organelles
themselves is easily achieved by simply suspending the
halobacteria in water with 1.0 mM MgSO4.
Conclusion
The studies presented here clearly demonstrate that
recombinant GvpC proteins displaying peptides encoded
by sequences from the three very different SIV genes each
are expressed, the translated proteins are incorporated
into the recombinant organelles and like native GvpC, the
recombinant proteins in turn are appropriately integrated
to produce functional organelles. The different chimeric r-
GvpC are detected in isolated gas vesicle preparations and
therefore the relevant incorporated gene sequences have
been retained by transformed SD109, and the r-GvpC pro-
teins themselves, are retained by the r-GV. The ELISA data
demonstrate the r-GV, with their highly ordered surfaces
serve as an effective display platform for peptide
sequences as an integral part of the r-GV surface structure.
Further, as shown by the ELISA data for serum samples
collected at 43 weeks post re-immunization, notably ele-
vated titers remained (Figures 8 and 9). From a practical
perspective it is also relevant that the recombinant
organelles also retain the natural gas vesicle functionality
since they clearly float to the air/5% NaCl interface. Thus,
like the wild type organelles, following halobacteria lysis
by transfer to hypotonic medium r-GV can be readily iso-
lated by centrifuge assisted flotation. Finally, from a pro-
duction standpoint, it is also significant that because a
standard bacterial cell wall is not present, the recom-
binant SD109, like the wild type Halobacterium sp. NRC-1,
require a high salt environment (≥ 5 M NaCl) to maintain
organism integrity. In the absence of high salt, the halo-
bacteria lyse and therefore for this recombinant, display
system, "escape" of viable halobacteria cannot occur. In
addition as sub-cellular organelles the r-GV, unlike the
various permutations of bacterial ghosts [33,34], contain
only a very limited number of "foreign" proteins. There-
fore in this they differ significantly from the complex array
of protein and carbohydrate inherently present in the bac-
terial ghost based delivery systems. Taken together, from
the perspective of cost and recombinant containment,
and extended retention of elevated humoral immune
response elicited, the submicroscopic particles that consti-
tute the halobacterial gas vesicle system have the potential
to provide an alternative antigen display and delivery sys-
tem. The ease of tailoring specific epitope presentations
inherent in the surface display of peptides by the organelle
would also support use of this system for displays to
screen for humoral responses to specific pathogen
epitopes, or as the peptide component in prime and boost
immunizations [35,36].
Methods
Plasmid design
Plasmid pFM101d (DasSarma and Morshed, unpublished
data [5,37]) carries the rightward gas vesicle operon and a
unique site for insertions within gvpC gene that restriction
enzyme Eco47 III cleaves (Figure 1); it was used in gener-
ating the three recombinant gvpC genes studied here. The
shuttle vector containing origins of replication for E. coli
and Halobacterium sp. NRC-1, and selectable drug resist-
ance markers, as well as genes for gas vesicles (GV) synthe-
sis [14,7] was re-constructed using plasmids pSP104,
pFM101d and pFM104::gag 504. Like pFM104d [19] this
plasmid, termed vector pMS104d contains Eco47 III
restriction site at the "d" location and all the genes neces-
sary for gas vesicle synthesis. It was used in the present
studies to generate the three different transformants pop-
ulations each of which incorporated one of gene segments
of interest, tat (150 bp), rev (243 bp) and nef1 (642 bp).
Amplification of SIVsm DNA and Preparation of Plasmids
PCR amplification of the SIV genomic fragments
Genomic sooty mangabey monkey (SIVsmm) template
DNA, a gift from Dr. V. Hirsch from NIH, was PCR ampli-
fied using standard recombinant technology methods
[38]. Briefly, based on the published SIVsmm proviral
genome sequence [GenBank: X14307], the primers neces-
sary to amplify the entire genome as 21 individual frag-
ments were designed, then synthesized commerciallyBMC Biotechnology 2008, 8:9 http://www.biomedcentral.com/1472-6750/8/9
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(Sigma-GenoSys, Woodlands TX). To restrict DNA seg-
ment sizes ≤ 650 bp, as necessary, genes were cleaved into
segments and numbered accordingly. The forward and
reverse primers for the fragments encoding SIVtat, rev and nef1
assessed in detail here, the relevant primers for gvpC
amplification and the amplified DNA fragment sizes are
shown in Table 1.
For each amplification, the 100 μl reaction mixture con-
tained the following: 10 μl of Thermophilic DNA
Polymerase 10× Buffer, Magnesium Free; 6 μl of Magne-
sium Chloride Solution, 25 mM; 2 μl of dNTP mixture
(Promega Corporation, Cat. # U1330, Madison WI), 2.5
mM; 0.5 μl Taq DNA Polymerase, 5 Units/μl; 3 μl of tem-
plate SIV DNA; 1 μl each of forward and reverse primers,
25 pmol; and 76.5 μl of ddH2O. The amplification pro-
gram was as follows: DNA denaturation at 95°C for 2
min, followed by 34 cycles of denaturation at 95°C for 30
sec, DNA annealing at 55°C for 30 sec, and extension at
72°C for 1 min followed by sample incubation at 72°C
for 5 min. The amplified DNA products were resolved
electrophoretically on agarose gels and visualized by
ethidium bromide staining.
Plasmid Preparation and Amplifications
As described in detail previously [19], the generation of
transformed Vac- (minus) halobacterial SD109 mutants
used a series of plasmids. The initial PCR products pro-
vided SIV fragments and following phosphorylation, the
selected SIV fragments and the pUC19 vector (New Eng-
land BioLabs, Beverly, MA), cleaved with Sma I, were
dephosphorylated using Shrimp Alkaline Phosphatase
(SAP, Roche Diagnostics Corporation, Indianapolis IN).
Fragments were gel purified and separately ligated with T4
ligase (Amersham Pharmacia Biotech, Inc; Piscataway,
NJ). E. coli cells (DH5α) were rendered competent using
the standard treatment with calcium chloride as detailed
previously [38,14], then transformed and the incorpo-
rated SIV DNA amplified. Each SIV containing insert was
subsequently removed by digesting the isolated plasmid
with Sma I. Vector pFM101d was cut with Eco47 III,
dephosphorylated using SAP, gel purified and subse-
quently the SIV inserts were blunt-end ligated into the
Eco47 III site of the gvpC gene contained in the plasmid
pFM101d shown in Figure 1. Aliquots of competent
DH5α cells (Invitrogen, Carlsbad, CA) were then trans-
formed with plasmids termed pFM101D::tat,::rev, and
::nef1 and grown in Luria broth (Fisher Scientific, Pitts-
burg, PA), containing 20 mM glucose and 100 μg/ml
Ampicillin (Sigma-Aldrich, St. Louis, MO), the selectable
marker for amplification in E. coli. Using the published
DNA sequences for gvpC and for each SIV fragment, plas-
mid DNA was assessed by PCR amplification to verify the
presence of SIVtat, rev or nef1 insertion using a gvpC forward
primer and the reverse primers for the respective tat, rev or
nef1 gene segments (Table 1). All plasmid constructs were
routinely characterized by restriction enzyme analysis and
after confirmation that the plasmid DNA included gvpC
containing the appropriate insert and orientation; they
were excised from pFM101D using Spe I and AsiS I (Figure
1). Following gel purification, the fragment with the right-
ward operon containing the tat, rev or  nef1  insert was
ligated into pMS104d, also cut with Spe I and AsiS I. The
resultant insert containing plasmids, pMS104D::tat, ::rev
and ::nef1 were verified by restriction enzyme digestion
and/or PCR analysis, then the plasmid construct with its
SIV DNA cassette insert was sequenced using an ABI
sequencer to verify the SIVsm inserts to confirm that no
deletions or mutations had occurred. Like pFM104d [19],
this plasmid, pMS104d is 18.9 Kb in size and contains the
origin of replication for halobacteria and the selectable
marker, mevinolin. Restriction enzymes were obtained
from New England Biolabs (Beverly, MA), DNA polymer-
ase from Promega (Madison, WI) and T4 DNA ligase was
included in the SureClone™ Ligation Kit (Amersham Phar-
macia Biotech, Inc; Piscataway, NJ); each component was
used as specified by the manufacturer. For final valida-
tion, cloned DNA or PCR amplified SIV fragments were
sequenced using an ABI 377XL automated DNA
sequencer at the Sequencing Facility at the University of
Massachusetts, Amherst or an ABI 3730 sequencer at the
Microbiology Department, in conjunction with the ABI
PRISM Big Dye Terminator v.3.1 cycle sequencing kit. Fol-
lowing sequence confirmation, the derived SIV sequence
containing plasmids, pMS104D::tat,:: rev and ::nef1 were
used to transform the Vac- (minus) halobacterial strain
SD109.
Growth and transformation of gas vesicle deficient 
Halobacterium sp. strain SD109
SD109, a mutant strain of Halobacterium sp. NRC-1 lack-
ing the gas vesicle gene cluster, is deficient in gas vesicle
formation. Using a modified protocol for transformation
of Halobacterium sp., recombinant plasmids each with one
of the SIVsm gene segment, were transformed into the
Vac- SD109. The methods used here are those optimized
for Halobacterium salinarium [6] and are described in detail
in the Archaea: A Laboratory Manual, Protocol 29 and
Appendix 2 [39]. Colonies were scored visually for the gas
vesicle phenotype (Vac+) and Vac+  colonies expanded
(Figure 4), using high salt peptone (Oxoid Ltd, Basing-
stoke, Hampshire, UK) with 10 μg/ml mevinolin as
described previously to select for the recombinants
[18,19].
Expansion of SD109 Transformant populations and gas 
vesicle isolation
Transformant populations were expanded using growth at
37°C on agar plates containing added trace metals
(ZnSO4, MnSO4, CuSO4 and FeSO4) and the selectiveBMC Biotechnology 2008, 8:9 http://www.biomedcentral.com/1472-6750/8/9
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antibiotic, mevinolin (CM+Mev+). Several colonies were
then selected from each transformation and grown in liq-
uid media under the same selective conditions. The reten-
tion of the inserted SIV DNA fragments was verified by
restriction analysis and validated transformant cultures
were grown at 37°C using larger plates to produce recom-
binant populations from which gas vesicles would be har-
vested. Gas vesicles from these transformed SD109 were
harvested by cell lysis using water containing 1.0 mM
magnesium sulfate and subsequently subjected to 3–5
rounds of centrifugally assisted flotation to isolate the
organelles from cell debris as described previously
[18,19]. Gas vesicle yields were first assessed spectropho-
tometrically (OD596) and then precise concentrations
were determined using the Biorad protein assay (BioRad
Laboratories, Hercules, CA). Isolated gas vesicles were
stored in 5% NaCl at 4°C.
Gas Vesicle Analyses
SDS-PAGE
Aliquots of isolated wt-GV and recombinant gas vesicles
(r-GVTat, Rev, or Nef1), dialyzed against distilled water, were
mixed with 5xSDS-PAGE sample buffer (Pierce-Endrogen,
Rockford, IL), and heated 5 min in a boiling water bath.
Then, 20–25 μl were loaded into wells of Novex pre-cast
8–16% or 12% gradient gels (Invitrogen, Carlsbad, CA)
and electrophoresed until the tracking dye reached the
bottom of the gel. Gels were stained with Coomassie Blue
R250 (Sigma-Aldrich, St. Louis, MO) or electroblotted for
Western analysis. MultiMark standards (Invitrogen,
Carlsbad, CA) and SeeBlue PreStained Standards (Invitro-
gen, Carlsbad, CA) were used to assess the molecular
weight (MW) of protein species.
Western blot
For Western blots, proteins were transferred from the SDS-
PAGE gel to Immobilon-P NC membrane or PVDF mem-
brane (Millipore, Bedford, MA) using a BioRad transfer
apparatus (BioRad, Hercules, PA) following the manufac-
turer's instructions. Subsequently, membranes were
blocked with 5% non-fat dry milk (NFDM) in phosphate
buffered saline (PBS; pH 7.2). This and all other incuba-
tions were carried out at RT on an orbital shaker. After
blocking for 2.5 h, membranes were rinsed three times
with 1% BSA/PBS, and then probed by incubation with
immune serum, or the appropriate control serum. GvpC
protein was detected using 0.020 μg/μl rabbit anti-GvpC
antibody diluted in 1% BSA/PBS. SIV peptides expressed
as part of the recombinant gas vesicle r-GvpC protein were
identified with monkey anti-SIV sera (RHE 544, a gift
from Dr. V. Hirsh, NIH). The SHIV-infected macaque
plasma (SHIV variant 89.6PD from the animal with
number R94085) was a gift from Dr. D. Pauza, Institute of
Human Virology, Baltimore, MD) [40]. These virus spe-
cific sera were diluted 1:150 or 1:200 respectively using
1% BSA/PBS; mouse anti-Nef1 sera were used at a 1:250
dilution. Following 1.5–2 h incubation with anti-sera
(SIV or SHIV), membranes were rinsed three times in 1%
BSA/PBS. Specifically bound antibody was detected by
incubation with either alkaline phosphatase conjugated
goat anti-rabbit IgG (H+L) chain (Jackson Immuno
Research, West Grove, PA) or with alkaline phosphatase
conjugated rabbit anti-monkey antibody (Sigma-Aldrich,
St. Louis, MO). Each conjugate was diluted 1:1,000 in 1%
BSA/PBS and incubation continued for 1 hour. Mem-
branes were rinsed three times with 1% BSA/PBS and two
times with dH2O, then incubated with the alkaline phos-
phatase membrane substrate, SigmaFast (Sigma-Aldrich,
St. Louis MO); protein bands developed within 5 min of
substrate addition. Subsequently blots were rinsed in dis-
tilled water; air dried at RT and archived as scanned
images.
Antigen preparation and immunizations
Mouse anti-SIV sera raised against protein encoded by SIV
DNA insert sequences was generated by immunizing
BALB/c mice (Jackson Laboratories, Bar Harbor, ME) with
subcutaneous injections of recombinant GV in sterile PBS
as outlined in the IACUC protocol specifically approved
for these studies. Sera from immunizations with the
expressed SIV inserts of Tat, Rev or Nef1 derived from gene
segments inserted into the gvpC gene. Sera were collected
from mice by tail bleed and the pre-bleed sera from these
same mice were pooled and used as a matched control
serum.
Briefly, to test immunogenecity, 4 month-old mice were
each injected subcutaneously at multiple sites on the
upper back initially using low dose immunization (1–3
μg total protein) with recombinant gas vesicles (r-GVTat,
Rev, or Nef1) in 200 μl sterile PBS. The boosters used 50 μg
total proteins per mouse; delivered in the same manner
[41]. Sera were collected by tail bleed 2 and 4 weeks after
primary immunization and at 4 weeks following the first
booster. After the second booster, sera were collected at 2,
4, 8, 12 and 17 weeks. Seventeen weeks after the 2nd
booster the mice were re-immunized using the same pro-
tein concentration and sera were collected 10 days later.
The animals were then retained for a total of 43 weeks
post-re-immunization and their sera were collected at that
final time point. Sera were subsequently adsorbed and
assayed by ELISA as described below.
Adsorption of immune sera and ELISA assays
Prior to ELISA antibody titration assays, immune sera
were adsorbed to remove any antibody directed against
the surface exposed wt-GvpC protein by incubations with
wt-GV. After serum adsorptions, the gas vesicles were
removed by 14,000 RPM centrifugation at room tempera-
ture (RT) which collapses the organelles, and the overly-BMC Biotechnology 2008, 8:9 http://www.biomedcentral.com/1472-6750/8/9
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ing serum was aspirated. Removal of anti-GV antibody
was verified by standard ELISA using wt-GV as antigen.
The test antigen used deflated (collapsed) gas vesicles pre-
pared as follows. Isolated gas vesicles produced by wt-
NRC1 or SD109 transformants were separately isolated,
then deflated by brief micro centrifuge centrifugation; this
drives the gas from the organelles yet retains the gas vesi-
cle intact. Deflated gas vesicles were diluted to 1 μg per
100 μl in PBS, (pH 7.2) and served as the specific SIVTat, Rev
or Nef1 peptide antigen. ELISA wells (Immobilon, Fisher
Scientific, Pittsburgh, PA) were filled with 100 μl of the
appropriate wt- or r-GVTat, Rev, or Nef1/PBS solution, and
then incubated for 1 hr at RT. After three rinses with PBS,
wells were blocked for 1 hr at RT with 200 μl per well of
3% BSA/PBS (Sigma-Aldrich, St. Louis, MO). Wells were
again rinsed with 200 μl PBS. Adsorbed immune mouse
sera or pre-bleed sera were serially diluted in 0.1% BSA/
PBS. Wells were filled with 100 μl of diluted sera and incu-
bated for 1 hr at RT, then rinsed 4 times with 200 μl of
0.1% BSA/PBS. Bound mouse immunoglobulin was
detected using alkaline phosphatase conjugated affinity
purified goat anti-mouse IgG (H+L) (Jackson Immuno
Research, West Grove, PA), diluted 1:1,000 in 0.1% BSA/
PBS; 100 μl was added to each well. Following 1 hr incu-
bation at RT, wells were rinsed five times with 0.1% BSA/
PBS then each well received 100 μl of pNPP substrate. The
pH 9.8 substrate contained distilled water with 10%
diethanolamine, 0.5 mM MgCl2, as a stabilizer (Fisher Sci-
entific, Pittsburgh, PA) and 1 mg/ml of Sigma 104 para-
nitrophenylphosphate (Sigma-Aldrich, St. Louis, MO).
Following an incubation of 60 or 90 min at 37°C, the
absorbance at 405 nm was quantified using a VersaMax
ELISA Reader (Molecular Devices, Palo Alto, CA). All sam-
ples were assayed in triplicate.
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